Zura Bio
ZURA

$3.89

4.77%

Market Cap: 248M

About: Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

Employees: 15

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

2% more funds holding

Funds holding: 44 [Q4 2023] → 45 (+1) [Q1 2024]

0.65% less ownership

Funds ownership: 34.82% [Q4 2023] → 34.17% (-0.65%) [Q1 2024]

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

47% less capital invested

Capital invested by funds: $70.7M [Q4 2023] → $37.6M (-$33.1M) [Q1 2024]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$16

311%

upside

Avg. target

$21

440%

upside

High target

$26

568%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Jeff Jones	440%upside $21	Outperform Maintained	10 May 2024
Piper Sandler Yasmeen Rahimi	568%upside $26	Overweight Initiated	3 May 2024
Oppenheimer Jeff Jones	311%upside $16	Outperform Reiterated	1 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ZURA published over the past 30 days

3 Undervalued Biotech Stocks With Breakout Potential

Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.

3 Undervalued Biotech Stocks With Breakout Potential

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (NASDAQ: ZURA) (“Zura Bio” or the “Company”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced an exchange offer (the “Offer”) and consent solicitation (the “Consent Solicitation”) relating to its outstanding (i) public warrants that were issued in connection with its initial public offering to purchase Class A ordinary shares of the Comp.

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

The 3 Most Undervalued Biotech Stocks to Buy in July 2024

There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.

The 3 Most Undervalued Biotech Stocks to Buy in July 2024

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today shared supportive data from a Phase 1 study evaluating its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's syndrome. These data, along with preclinical data supporting further development of tibulizumab in rheumatoid arthritis (RA), were presented at the Annual European Co.

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists.

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced it will present data from its tibulizumab (ZB-106) program exploring the clinical potential of the dual-pathway antibody in Sjogren's syndrome and rheumatoid arthritis (RA) at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab (ZB-106.

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

Zacks Investment Research

Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know

The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know

Zura Bio Announces Participation in June Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June. Conference Details: Event: Jefferies Global Healthcare Conference Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetin.

Zura Bio Announces Participation in June Investor Conferences

3 Penny Stocks to Buy Now: May 2024

Penny stocks to buy carry a considerable amount of risk. That's why we include the disclaimer at the tail-end of this article.

3 Penny Stocks to Buy Now: May 2024

Zacks Investment Research

How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%

See News Rankings